房地产板块震荡走弱，盈新发展、香江控股触及跌停，冠城新材、三木集团、天健集团、华丽家族、荣 盛发展、福星股份等跟跌。 ...

Core Viewpoint - The stock price of Huayi Family has shown a significant increase of 25.77% year-to-date, with recent trading activity indicating a mixed performance in the short term [2] Group 1: Stock Performance - As of November 5, Huayi Family's stock rose by 2.19%, reaching 3.27 CNY per share, with a trading volume of 72.72 million CNY and a turnover rate of 1.40% [1] - The stock has experienced a 2.83% increase over the last five trading days, a 0.91% decrease over the last 20 days, and a 23.86% increase over the last 60 days [2] Group 2: Financial Performance - For the period from January to September 2025, Huayi Family reported a revenue of 169 million CNY, representing a year-on-year decrease of 35.56%, and a net profit attributable to shareholders of -26.06 million CNY, a significant decline of 1639.78% [2] - Cumulative cash dividends since the company's A-share listing amount to 451 million CNY, with 6.41 million CNY distributed over the past three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Huayi Family was 113,000, a decrease of 6.18% from the previous period, while the average circulating shares per person increased by 6.59% to 14,179 shares [2] - The third-largest circulating shareholder is the Southern CSI Real Estate ETF, holding 20.25 million shares, which is a reduction of 204,700 shares compared to the previous period [3]

Group 1 - The core viewpoint of the articles highlights the changes in institutional and foreign investment in Huayi Family (600503.SH) as of Q3 2025, indicating a slight decline in institutional holdings and mixed trends in foreign fund investments [1][2] Group 2 - As of October 28, 2025, seven institutional investors hold a total of 206 million shares of Huayi Family, accounting for 12.83% of the total share capital, with a decrease of 0.73 percentage points compared to the previous quarter [1] - The public fund holdings saw a decrease with one fund, Southern CSI All Share Real Estate ETF, reducing its stake, while eight funds were not disclosed this quarter, including major ETFs and quantitative funds [1] - Among foreign investors, J.P. Morgan Securities PLC increased its holdings slightly, while Morgan Stanley and Swiss Bank of Geneva reduced their stakes by 1.07% [2] - A new foreign institution, Barclays Bank PLC, was disclosed this quarter, indicating ongoing interest from foreign investors [2]

Core Viewpoint - The company, 华丽家族, reported its third-quarter operational data for 2025, highlighting both growth and decline in various metrics related to its real estate business. Financial Data Summary - For the first nine months of 2025, the company signed a total area of 26,200 square meters, an increase of 4.64% compared to 25,100 square meters in the same period last year [9]. - In the third quarter of 2025, the signed area was 9,000 square meters, a significant decrease of 53.02% from 19,100 square meters in the same quarter of the previous year [10]. - The total signed amount for the first nine months of 2025 reached 484.04 million yuan, up 37.96% from 350.85 million yuan year-on-year [11]. - In the third quarter of 2025, the signed amount was 285.49 million yuan, which is a 22.93% increase from 232.23 million yuan in the same period last year [12]. Real Estate Development Summary - The company reported no new real estate reserve area for both the first nine months and the third quarter of 2025, compared to an addition of 4,400 square meters in the same period last year [13][14]. - The company completed 60,300 square meters of new construction in the first nine months of 2025, whereas there was no completed area in the same period last year [15]. - In the third quarter of 2025, the company added 53,200 square meters of new construction, again with no completed area in the same quarter of the previous year [16]. - The new construction area for the first nine months of 2025 was 48,500 square meters, a decrease of 44.40% from 87,200 square meters year-on-year [16]. - There was no new construction area reported in the third quarter of 2025, consistent with the previous year [17].

Core Insights - The company reported a revenue of 169 million yuan for the first three quarters of 2025, representing a year-on-year decline of 35.56% [1] - The net profit attributable to shareholders was a loss of 26.06 million yuan [1] - The non-recurring net profit also showed a loss of 28.22 million yuan, with a basic earnings per share of -0.0163 yuan [1]

证券代码：600503 证券简称：华丽家族 公告编号：临2025－035 根据上海证券交易所《上海证券交易所上市公司自律监管指引第3号——行 业信息披露》的要求，现将华丽家族股份有限公司（以下简称"公司"）2025年第 三季度房地产业务主要经营数据公告如下： 2025年1-9月，公司签约面积为2.62万平方米，上年同期为2.51万平方米，同 比上升4.64%。 2025年7-9月，公司签约面积为0.90万平方米，上年同期为1.91万平方米，同 比下降53.02%。 2025年1-9月，公司签约金额为48,404.12万元，上年同期为35,084.91万元， 同比上升37.96%。 华丽家族股份有限公司 2025年1-9月，公司新增竣工面积6.03万平方米，上年同期无竣工面积。 2025 年第三季度房地产业务主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025年7-9月，公司签约金额为28,548.80万元，上年同期为23,222.85万元， 同比上升22.93%。 2025年1-9月，公司无新增房地产储备 ...

Financial Performance - The company's operating revenue for the third quarter was CNY 31,376,634.95, a decrease of 70.52% compared to the same period last year[5] - The total profit for the quarter was a loss of CNY 15,888,310.92, representing a decline of 540.64% year-on-year[5] - The net profit attributable to shareholders was a loss of CNY 15,645,044.96, with a year-to-date loss of CNY 26,057,463.00, reflecting a decrease of 1,639.78%[5] - Total revenue for the first three quarters of 2025 was CNY 169,351,178.50, a decrease of 35.5% compared to CNY 262,802,218.50 in the same period of 2024[21] - Operating profit for the first three quarters of 2025 was a loss of CNY 27,268,215.64, compared to a profit of CNY 13,502,763.70 in 2024[22] - Net profit for the first three quarters of 2025 was a loss of CNY 26,544,627.96, compared to a profit of CNY 2,028,787.97 in the same period of 2024[22] - Basic and diluted earnings per share for the first three quarters of 2025 were both CNY -0.0163, compared to CNY 0.0011 in 2024[23] Cash Flow and Assets - The cash flow from operating activities for the year-to-date was CNY 76,104,823.69[6] - The net cash flow from operating activities for the current period is 155.11 million RMB, primarily due to an increase in advance payments received from subsidiaries[11] - Operating cash inflow totaled $461.14 million, up from $286.29 million year-over-year[26] - Net cash flow from operating activities was $76.10 million, a significant improvement from a net outflow of $299.28 million in the previous period[26] - Total cash outflow from operating activities was $385.04 million, compared to $585.57 million in the prior year[26] - The ending cash and cash equivalents balance was $739.98 million, down from $769.94 million at the end of the previous period[27] Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,664,804,552.05, an increase of 5.19% from the end of the previous year[6] - The total current assets as of September 30, 2025, amount to 3,481.70 million RMB, showing a slight increase from 3,465.36 million RMB at the end of 2024[18] - Total liabilities increased to CNY 1,042,711,329.50 from CNY 786,084,943.34, representing a growth of 32.6%[20] - Non-current liabilities totaled CNY 303,750,578.82, up from CNY 276,835,299.07, indicating an increase of 9.5%[20] - The company reported a significant increase in contract liabilities, rising to CNY 388,119,826.83 from CNY 178,543,196.34, a growth of 117.0%[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 112,998, with the largest shareholder holding 7.12% of the shares[14] - The equity attributable to shareholders decreased by 0.73% to CNY 3,554,540,009.19 compared to the end of the previous year[6] Investment and Expenses - Long-term equity investments decreased by 82.78 million RMB due to project exits during the year-to-date[11] - The company reported an increase in other income of 482.67 million RMB, attributed to penalties received as per contract agreements[11] - Research and development expenses were reported at -100.00 million RMB, indicating no R&D investment during the year-to-date[11] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[28]

Core Insights - The company reported a significant decline in revenue and net profit for the third quarter, indicating ongoing financial challenges [1] Financial Performance - Q3 revenue was 31.3766 million yuan, a year-on-year decrease of 70.52% [1] - Q3 net profit showed a loss of 15.645 million yuan [1] - Revenue for the first three quarters totaled 169 million yuan, down 35.56% year-on-year [1] - The net profit loss for the first three quarters was 26.0575 million yuan [1]

Core Points - The stock price of Huayi Family has decreased by 2.09% to 3.28 CNY per share as of October 20, with a market capitalization of 5.256 billion CNY [1] - Year-to-date, the stock has increased by 26.15%, but has seen a decline of 0.91% in the last five trading days and 11.83% in the last 20 days [2] - The company has been on the "Dragon and Tiger List" five times this year, with the most recent instance on August 21, where it recorded a net buy of -65.618 million CNY [2] Financial Performance - For the first half of 2025, Huayi Family reported a revenue of 138 million CNY, a year-on-year decrease of 11.76%, and a net profit attributable to shareholders of -10.4124 million CNY, a decrease of 437.58% [2] - Cumulative cash dividends since the A-share listing amount to 451 million CNY, with 6.4092 million CNY distributed over the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders is 120,400, a decrease of 6.75% from the previous period, with an average of 13,303 circulating shares per person, an increase of 7.24% [2] - The third-largest circulating shareholder is the Southern CSI Real Estate ETF, holding 20.4562 million shares, an increase of 441,500 shares from the previous period [3]

Core Points - Shanghai Haihe Pharmaceutical Co., Ltd. has entered into an exclusive licensing agreement with Japan's Daikyo Pharmaceutical Co., Ltd. for the development, production, and commercialization of the PI3Kα inhibitor, CYH33, in Japan [1] - This collaboration follows a previous agreement between Haihe Pharmaceutical and Daikyo Pharmaceutical regarding the MET inhibitor, Gomitil, which has successfully been approved for sale in both China and Japan [1] - The agreement will provide Haihe Pharmaceutical with an upfront payment, milestone payments based on development and sales, and royalties based on sales in Japan [1] Group 1 - The partnership highlights Daikyo Pharmaceutical's recognition of Haihe Pharmaceutical's research capabilities [2] - The collaboration reflects Haihe Pharmaceutical's strategy of "Chinese innovation, global layout," supported by the capital investment from Huayi Family [2] - Huayi Family's investment has facilitated Haihe Pharmaceutical's research and global expansion, enhancing the stability and speed of its innovative drug's international journey [2]